HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.

AuthorsT L Lasho, A Mims, M A Elliott, C Finke, A Pardanani, A Tefferi
JournalLeukemia (Leukemia) Vol. 28 Issue 6 Pg. 1363-5 (Jun 2014) ISSN: 1476-5551 [Electronic] England
PMID24445868 (Publication Type: Case Reports, Letter)
Chemical References
  • Antineoplastic Agents
  • CSF3R protein, human
  • Carrier Proteins
  • Nitriles
  • Nuclear Proteins
  • Pyrazoles
  • Pyrimidines
  • Receptors, Colony-Stimulating Factor
  • SETBP1 protein, human
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2
  • Hydroxyurea
Topics
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Breast Neoplasms (complications, therapy)
  • Carrier Proteins (genetics)
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm (drug effects)
  • Erythroid Cells (drug effects, metabolism, pathology)
  • Female
  • Granulocytes (drug effects, metabolism, pathology)
  • Humans
  • Hydroxyurea (therapeutic use)
  • In Vitro Techniques
  • Janus Kinase 2 (antagonists & inhibitors)
  • Leukemia, Neutrophilic, Chronic (drug therapy, etiology, pathology)
  • Mutation (genetics)
  • Nitriles
  • Nuclear Proteins (genetics)
  • Prognosis
  • Pyrazoles (therapeutic use)
  • Pyrimidines
  • Receptors, Colony-Stimulating Factor (genetics)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: